Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst , Paul Baas , DongâWan Kim +16 more 2015 The Lancet 6378 citations